Friday, February 3, 2023
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
Daily Remedy
  • Home
  • Articles
  • Podcasts
    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    November 25, 2022
    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    November 25, 2022
    A conversation with Dr. Edwin Leap, physician writer and emergency medicine physician

    A conversation with Dr. Edwin Leap, writer and emergency medicine physician

    November 8, 2022
    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    October 31, 2022
    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    October 23, 2022
    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    October 23, 2022
  • Surveys

    Surveys

    Does inflation affect how you use your deductible?

    Does inflation affect how you use your deductible?

    by Jay K Joshi
    December 12, 2022

    Survey Resutls

    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    October 16, 2022
  • About Us
  • Contact us
  • Support Us
  • Purchase DME
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    A conversation with Dr. Selwyn O. Rogers, trauma surgeon and gun policy expert

    November 25, 2022
    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    A conversation with Dr. Kyle Fischer, policy director for the Health Alliance for Violence Intervention

    November 25, 2022
    A conversation with Dr. Edwin Leap, physician writer and emergency medicine physician

    A conversation with Dr. Edwin Leap, writer and emergency medicine physician

    November 8, 2022
    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    A conversation with Mr. Omar M Khateeb, innovator in medical device sales

    October 31, 2022
    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    A conversation with Miss Smriti Kirubanandan, passionate healthcare strategist

    October 23, 2022
    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    A conversation with Mr. Michael Johnson, legal expert in physician contracts

    October 23, 2022
  • Surveys

    Surveys

    Does inflation affect how you use your deductible?

    Does inflation affect how you use your deductible?

    by Jay K Joshi
    December 12, 2022

    Survey Resutls

    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    October 16, 2022
  • About Us
  • Contact us
  • Support Us
  • Purchase DME
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Politics & Law

The Court of FDA

Jay K Joshi by Jay K Joshi
September 6, 2022
in Politics & Law
0
The Court of FDA

Men lie, women lie, but the numbers never lie: or so the saying goes. But in following the FDA, it seems they bend data to varying degrees of transparency and truthfulness.

Through this kaleidoscope of distortions, the FDA has made decisions that defy traditional scrutiny of clinical data. The most egregious example of late is the FDA’s decision to allow pharmacists to prescribe Paxlovid, an anti-viral medication that helps relieve COVID related complications among symptomatic patients.

It comes as a response to calls asking for more access to COVID-19 treatments. But curiously, the same access was not provided to a competitor drug, Lagevrio.

“The FDA has determined that Lagevrio should only be prescribed by traditional prescribers,” the FDA wrote in an email. “This determination is based on several factors, including the drug’s side effect profiles and the need for provider-patient consultation.”

But according to a federal claims database, more than 40 percent of adults diagnosed with COVID were at risk for drug-drug interactions (DDIs) that would disqualify them for Paxlovid. At such a high percentage, it is unclear what side effect profiles distinguish Paxlovid from Lagevrio.

This is to say nothing about the existing data on Paxlovid. As incredulous as it may sound, Paxlovid, which is prioritized for high risk patients, presumably elderly patients who have already been vaccinated three if not four times already, has never been formally studied in vaccinated populations. It appears the FDA does not like data from randomized controlled trials.

The FDA also seems to dislike a consistent approach to public health issues. It most recently grabbed media attention by announcing and then quickly softening its stance on banning vaping products from the company Juul, the market leader in electronic cigarette products.

The move came as concerns grew that adolescents were abusing vaping products and suffering acute lung injuries. Never mind the benefits these products hold for patients seeking to quit traditional cigarettes. No, the FDA focuses more on the risk of diversion and abuse among those who willfully misuse a product than the intended benefits the product confers.

As a result, a ban was issued and then retracted. And the FDA and Juul are on another collision course in which antiquated notions of moralization confront clinical principles of harm reduction. Which is bad enough, but what makes the entire ordeal bizarre is the FDA’s contradictory stance on abortion access and birth control medications.

In recent weeks, the FDA announced it is considering approving an over-the-counter birth control pill, which would be the first of its kind. And it has no plans to curb access to abortion medications anytime soon. The agency made it clear that it supports access to such medications as a fundamental medical right.

Apparently, the FDA believes that harm reduction applies to pregnancies and safe sex practices, but not to cigarette smoking.

These oddities extend beyond the FDA’s decision-making. It cannot even manage its site inspections properly. We know of the inspection debacle leading to a national baby formula shortage. It has been well covered. But it is far from an anomaly. Just recently, a similar situation led to a delay in Monkeypox vaccine production following a delay in a site inspection by the FDA – right when the virus is spreading across the globe.

All of this alludes to a sense of incompetence; that the FDA does not know what it is doing, and makes decisions or takes actions on a whim, without a clear regard for consequence or consistency. But the truth is far more subtle, far more pernicious.

The FDA is rife with inconsistencies and errors because it has conflicting interests that lead to all manners of incentives. Just look at the FDA’s attempt to lower drug prices. The FDA made any pursuit of fair competitive practices among generic and biosimilar drugs practically impossible. It now requires new entrants seeking to manufacture low cost generic drugs to declare their intention to manufacture through a series of announcements that stand for one to two years. What these announcements consist of and to whom they need to be reported are poorly defined and overtly subjective. Not to mention a one to two year span is hardly enough time to ramp up manufacturing for drugs that can easily take a decade to manufacture.

These convoluted practices are by design. It feigns incompetence as a cover for malfeasance. And it reveals the many layers of perverse incentives within the FDA. Through such a system, the FDA decrees decisions without proper diligence of any data. All that is needed is the veneer of oversight laden with jargon-rich buzzwords that give off the pretense of authority.

In a way, the FDA has become its own court of sorts, acting as judge, jury, and executioner, all in one.

ShareTweet
Jay K Joshi

Jay K Joshi

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

YouTube Video VVUxUDVQenU5RTFjUVFKNDY2ZlBmdFB3LmdVUm55WVpqRmNn This is a video about Elemental/Essential Frameworks of Healthcare Law

00:00 Elemental/Essential Frameworks of Healthcare Law
Load More... Subscribe

Expert vs. Lay Testimony

Visuals

NADAC (National Average Drug Acquisition Cost)

NADAC (National Average Drug Acquisition Cost)

by Jay K Joshi
January 29, 2023
0

We list the acquisition price of drugs that are covered under the Medicaid Drug Rebate Program - effectively, how much does the government pay for common drugs utilized by patients on Medicaid. Drugs listed are from A-CH.  

Read more

Twitter Updates

Tweets by DailyRemedy1

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

Popular

  • Malicious Prosecution and Fabrication of Evidence

    Malicious Prosecution and Fabrication of Evidence

    0 shares
    Share 0 Tweet 0
  • 2022 Letter to the American Medical Association

    0 shares
    Share 0 Tweet 0
  • 2023 Letter to the American Medical Association

    0 shares
    Share 0 Tweet 0
  • Letter to the Alabama Board of Medical Examiners

    0 shares
    Share 0 Tweet 0
  • Prosecuting Doctors as Drug Dealers

    0 shares
    Share 0 Tweet 0

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2023 Daily Remedy

No Result
View All Result
  • Home
  • Articles
    • Contrarian
    • Financial Markets
    • Innovations & Investing
    • Perspectives
    • Politics & Law
    • Trends
    • Uncertainty & Complexity
  • Podcasts
  • Surveys
    • Survey Results
  • About Us
  • Contact us
  • Support Us

© 2023 Daily Remedy

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do